# Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

> **NCT03332576** · PHASE1 · COMPLETED · sponsor: **ImmunoVaccine Technologies, Inc. (IMV Inc.)** · enrollment: 37 (actual)

## Conditions studied

- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer

## Interventions

- **BIOLOGICAL:** DPX-Survivac
- **BIOLOGICAL:** DPX-Survivac(Aqueous)
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03332576
- **Lead sponsor:** ImmunoVaccine Technologies, Inc. (IMV Inc.)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08-23
- **Primary completion:** 2016-09-08
- **Final completion:** 2019-09-09
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2021-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03332576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03332576, "Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03332576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*